SLR Capital Partners has a dedicated team of life science investment professionals who specialize in providing 1st lien senior secured loans to venture capital backed private and publically-traded healthcare companies. Borrowers are typically later stage drug and medical device development, diagnostic, healthcare IT and healthcare services companies, with substantial equity invested to date. We focus on late clinical and early commercial stage companies with disruptive technologies that are backed by top-tier institutional investors, led by experienced management teams, and guided by a strong board of directors.
SLR launched the Solar Life Science Finance platform in Q1 2014 with the hiring of the leader of GE Capital’s life science finance business, which he founded in 2001. With the addition a year later of the core investment team from GE Capital that had worked with the founder since 2003, SLR's life science investment team is now comprised of a core group of experienced professionals with deep industry expertise who have worked together for over 18 years.
From inception, the team has invested approximately $3.4 billion in life science companies, including originating over $1.1 billion in over 68 transactions since joining the SLR platform. The team’s strong track record and deep relationships with VCs, CEOs and CFOs has enabled them to successfully differentiate themselves from other lenders in the space.
Later stage drug and medical device development, diagnostic, healthcare IT, healthcare services companies with:
Multi-product pipeline / platform / disruptive technologies
Strong institutional / strategic investor support
Broad and protected intellectual property position
Experienced management and board
For additional information: Lifescience@slrcp.com